E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
NON−SMALL CELL LUNG CANCER |
|
E.1.1.1 | Medical condition in easily understood language |
NON−SMALL CELL LUNG CANCER |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10029514 |
E.1.2 | Term | Non-small cell lung cancer NOS |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of atezolizumab monotherapy treatment compared with best supportive care as measured by disease-free survival (DFS) as assessed by the investigator in PD-L1-selected populations within the Stage II-IIIA subpopulation, in all randomized Stage II–IIIA patients, and in the ITT population
|
|
E.2.2 | Secondary objectives of the trial |
To evaluate the efficacy of atezolizumab monotherapy treatment compared with BSC as measured by overall survival (OS) in ITT population; 3-year and 5-year DFS rates in the PD-L1-selected populations within the Stage II-IIIA subpopulation, in all-randomized patients with Stage II-IIIA NSCLC, and in the ITT population and by DFS within the PD-L1-selected populations in the evaluable Stage II-IIIA subpopulation and within the evaluable ITT population |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- A representative formalin-fixed paraffin-embedded (FFPE) tumor specimen in paraffin block (preferred) or 15 (or more) unstained, freshly cut, serial sections (on slides) from an FFPE resected tumor specimen is required for participation in this study. This specimen must be accompanied by the associated pathology report - ECOG performance status of 0 or 1 - Histological or cytological diagnosis of Stage IB (tumors ≥ 4 cm)−IIIA (T2−3 N0, T1−3 N1, T1-3 N2, T4-N0 1) non-small cell lung cancer (NSCLC) - Eligible to receive a cisplatin-based chemotherapy regimen - For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception during study treatment that results in a low failure rate of < 1% per year when used consistently and correctly. Female and male patients should continue contraceptive use for 6 months after the last dose of cisplatin-based chemotherapy (cisplatin plus vinorelbine, docetaxel, gemcitabine, or pemetrexed). Female patients treated with atezolizumab should continue contraception use for 5 months after the last dose. Women must refrain from donating eggs during this same period
|
|
E.4 | Principal exclusion criteria |
- Illness or condition that may interfere with a patient’s capacity to understand, follow, and/or comply with study procedures - Pregnant and lactating women - Treatment with prior systemic chemotherapy, with the following exceptions: •Chemotherapy for early stage of malignancy with curative intent, provided that the last dose received was more than 5 years prior to enrollment, may be allowed upon approval by the Medical Monitor •Low-dose chemotherapy for non-malignant conditions may be allowed upon approval by the Medical Monitor - Hormonal cancer therapy or radiation therapy as prior cancer treatment within 5 years before enrollment - Treatment with any other investigational agent with therapeutic intent within 28 days prior to enrollment - Known sensitivity to any component of the chemotherapy regimen the patient will be assigned to, or to mannitol - Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-PD-1, and anti-PD-L1 therapeutic antibodies - Patients who have had prior anti-CTLA-4 treatment may be enrolled, provided the following requirements are met: •Last dose of anti-CTLA-4 at least 6 weeks prior to randomization •No history of severe immune-mediated adverse effects from anti-CTLA-4 (NCI CTCAE Grades 3 and 4) - Known tumor PD-L1 expression status as determined by an IHC assay from other clinical studies (e.g., patients whose PD-L1 expression status was determined during screening for entry into a study with anti-PD-1 or anti-PD-L1 antibodies but were not eligible are excluded)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
1.-DFS, defined as the time from randomization to the date of occurrence of any of the following, whichever occurs first: •First recurrence of NSCLC, as determined by the investigator after an integrated assessment of radiographic data, biopsy sample results (if available), and clinical status •Occurrence of new primary NSCLC, as assessed by the investigator •Death from any cause |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1.-OS, defined as the time from randomization to death from any cause 2.-DFS rates at 3 years and 5 years in the PD-L1-selected and all-randomized populations for Stage II-IIIA, and in the ITT population 3.-DFS within the PD-L1-selected populations in the evaluable Stage II-IIIA subpopulation and within the evaluable ITT population
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1-3 Approximately 5 years |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 119 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belgium |
Canada |
China |
France |
Germany |
Hong Kong |
Hungary |
Israel |
Italy |
Japan |
Korea, Republic of |
Netherlands |
Poland |
Portugal |
Romania |
Russian Federation |
Spain |
Taiwan |
Ukraine |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as the latter of the dates of when 433 deaths have occurred in the global main study’s ITT population and 355 deaths have occurred in the Stage II−IIIA subpopulation. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 0 |